| Tamoxifen-induced apoptosis of MCF-7 cells via GPR30/PI3K/MAPKs interactions: Verification by ODE modeling and RNA sequencing M Rouhimoghadam, S Safarian, JS Carroll, N Sheibani, G Bidkhori Frontiers in physiology 9, 907, 2018 | 41 | 2018 |
| Therapeutic perspectives on the modulation of G-protein coupled estrogen receptor, GPER, function M Rouhimoghadam, AS Lu, AK Salem, EJ Filardo Frontiers in Endocrinology 11, 877, 2020 | 39 | 2020 |
| Proteolytic targeting chimeras with specificity for plasma membrane and intracellular estrogen receptors AS Lu, M Rouhimoghadam, CK Arnatt, EJ Filardo, AK Salem Molecular pharmaceutics 18 (3), 1455-1469, 2021 | 19 | 2021 |
| Exploiting LY3009120 and Asciminib Combination to Target TKI-Resistant CML M Rouhimoghadam, AD Pomicter, A Van Scoyk, G Poffenberger, I Kirov, ... Blood 138, 3600, 2021 | 2 | 2021 |
| Gper proteolytic targeting chimeras AK Salem, EJ Filardo, AS Lu, M Rouhimoghadam US Patent App. 17/920,645, 2023 | 1 | 2023 |
| LPA81: Discovery of an Exceptionally Potent Protac Degrading Native and Mutant BCR-ABL1 Oncoprotein in CML M Rouhimoghadam, H Tang, J Liao, B Bates, D Uribe-Cano, H Zhao, ... Blood 140, 485-486, 2022 | 1 | 2022 |
| Discovery of a Selective PROTAC Degrading Untamable BCR:: ABL1 Compound Mutants in Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute … M Rouhimoghadam, H Tang, B Bates, J Liao, D Uribe-Cano, W Tang, ... Clinical Lymphoma, Myeloma and Leukemia 23, S336, 2023 | | 2023 |
| Therapeutic Perspectives on the Modulation of G-Protein Coupled Estrogen Receptor, GPER, Function SH Lindsey, M Maggiolini, RR Tekmal, H Hathaway, EJ Filardo, ... GPER and Human Pathologies, 2022 | | 2022 |
| Development of cancer therapeutic capable of selective proteolytic targeting of G-protein coupled estrogen receptor, GPER M Rouhimoghadam, A Lu, A Salem, E Filardo Holden Comprehensive Cancer Center Scientific Retreat, 2020 | | 2020 |
| Rescue of misfolded G-protein coupled estrogen receptor, GPER, from the endoplasmic reticulum via natural and synthetic estrogens M Rouhimoghadam, J Dong, P Thomas, EJ Filardo Journal of the Endocrine Society 4, 2020 | | 2020 |
| Harnessing gut microbiome-mediated metabolism of the natural isoflavone daidzein to treat breast cancer M Rouhimoghadam, J Dunning, N Cady, A Mangalam, EJ Filardo 28th Annual Biocatalysis and Bioprocessing Conference, 2019 | | 2019 |
| Majority of TP53 signaling pathway related genes are up-regulated in Tamoxifen-treated MCF-7 human Breast adenocarcinoma cell line M Rouhimoghadam, S Shahrokh The 2nd International Personalized Medicine Congress, With Cancer Main Topics, 2018 | | 2018 |
| Tamoxifen is a putative substrate that affect the ubiquitin-proteasome pathway to the therapy of breast cancer M Rouhimoghadam, S Shahrokh, JS Carroll 2nd International Congress on Biomedicine, Tehran, 2018 | | 2018 |
| Tamoxifen-induced rapid death of GPER positive cell lines by modulating RAS/MAPK signaling pathway M Rouhimoghadam, S Shahrokh, JS Carroll 1st International Congress on Biomedicine, Tehran, Iran, 2017 | | 2017 |
| HER-2 V777L mutation detection using HRMA based Real-Time PCR in Breast Cancer M Rouhimoghadam, A Shahoseini | | 2016 |
| Computational modelling of Crosstalk between GPR30 and EGFR signalling Network in Normal Cells M Rouhimoghadam, G Bidkhori, S Shahrokh ICSB 2014, 2014 | | 2014 |
| Study of Anti-tumoral Effects of Tamoxifen on MDA-MB-231 Breast Cancer Cell Line in the presence of Quercetin M Rouhimoghadam, SJ Zargar, S Safarian | | 2014 |
Edward FilardoUniversity of IowaVerified email at starlingpharmaceuticals.com
